Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-02
DOI
10.1007/s40264-020-00968-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
- (2020) G.R. Oxnard et al. ANNALS OF ONCOLOGY
- WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information
- (2020) Olof Lagerlund et al. Therapeutic Innovation & Regulatory Science
- Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
- (2019) Natsumi Namba et al. ANNALS OF THE RHEUMATIC DISEASES
- Severe immune related adverse events are common with sequential PD-(L)1 blockade and osimertinib
- (2019) A J Schoenfeld et al. ANNALS OF ONCOLOGY
- Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports
- (2019) Rika Wakao et al. DRUG SAFETY
- Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease
- (2019) Chihiro Udagawa et al. PLoS One
- EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
- (2018) Yasuo Oshima et al. JAMA Oncology
- MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
- (2018) Pierre-Antoine Juge et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-Induced Interstitial Lung Disease: A Systematic Review
- (2018) Sarah Skeoch et al. Journal of Clinical Medicine
- A method for data-driven exploration to pinpoint key features in medical data and facilitate expert review
- (2017) Kristina Juhlin et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Analysis of safety-related regulatory actions by Japan's pharmaceutical regulatory agency
- (2017) Chieko Ishiguro et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
- (2016) Meiko Nishimura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
- (2016) Rashmi R. Shah DRUG SAFETY
- Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance
- (2016) Luis Pinheiro et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR)
- (2012) Kazuhiko Nakagawa et al. Journal of Thoracic Oncology
- Interstitial Lung Disease in Japanese Patients with Lung Cancer
- (2008) Shoji Kudoh et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started